As adverse side effects or potential safety signals trigger increasing regulatory scrutiny of primary care drugs, large pharmaceutical companies have increasingly looked to obtain—either via licensing deals or acquisitions—access to specialty drugs, particularly in the area of oncology where high unmet medical need and a dearth of treatments offer the promise of an easier path to market. This spring, for instance, Takeda Pharmaceutical Co. Ltd. spent $8.2 billion to acquire Takeda Oncology to obtain rights to bortezomib (Velcade), while Bristol-Myers Squibb Co. ponied up $235 million for Kosan Biosciences Inc., adding two new classes of drugs, epithilones and Hsp90 inhibitors, to its stable of cytotoxic oncology medicines. [See Deal][See Deal]
Glioblastoma Start-Ups Get Specific
For start-ups developing novel and risky medicines to treat glioblastoma, a rare, invasive form of brain cancer, the Pfizer/Avant deal was a watershed moment: It signaled the vigorous interest of a pharmaceutical behemoth in a disease where patients number in just the tens of thousands. The positive effects are likely to be felt in executive suites of biotechs developing therapeutics for this grievous disease.
More from Strategy
More from Business
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.